ID: ALA3893064

Max Phase: Preclinical

Molecular Formula: C18H13N5O5

Molecular Weight: 379.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(/C=C/c1ccc([N+](=O)[O-])cc1)c1cn(Cc2ccc([N+](=O)[O-])cc2)nn1

Standard InChI:  InChI=1S/C18H13N5O5/c24-18(10-5-13-1-6-15(7-2-13)22(25)26)17-12-21(20-19-17)11-14-3-8-16(9-4-14)23(27)28/h1-10,12H,11H2/b10-5+

Standard InChI Key:  CVKOJPBBOPIMAL-BJMVGYQFSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 379.33

Molecular Weight (Monoisotopic): 379.0917

AlogP: 3.04

#Rotatable Bonds: 7

Polar Surface Area: 134.06

Molecular Species: NEUTRAL

HBA: 8

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 3.93

CX LogD: 3.93

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.27

Np Likeness Score: -1.28

References

1.  (2015)  Cinnamoyl inhibitors of transglutaminase, 

2. Apperley KYP, Roy I, Saucier V, Brunet-Filion N, Piscopo SP, Pardin C, De Francesco É, Hao C, Keillor JW..  (2017)  Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition.,  8  (2): [PMID:30108749] [10.1039/C6MD00565A]

Source

Source(2):

• Scientific Literature
• BindingDB Database